Collaborations, Facility Expansions, and Regulatory Approvals Open Opportunities for Revenue Growth - Research Report on Johnson

      Collaborations, Facility Expansions, and Regulatory Approvals Open
   Opportunities for Revenue Growth - Research Report on Johnson & Johnson,
                 Zoetis, CVS Caremark, Omnicare, and Novartis

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 12, 2013

NEW YORK, July 12, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Johnson
& Johnson (NYSE: JNJ), Zoetis Inc. (NYSE: ZTS), CVS Caremark Corporation
(NYSE: CVS), Omnicare, Inc. (NYSE: OCR), and Novartis AG (ADR) (NYSE: NVS).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On July 2, 2013, Mentor Worldwide LC (Mentor), a Johnson & Johnson (Johnson &
Johnson) company, announced that it has entered into a 5 year Collaboration
Agreement (agreement) with the Medicis division (Medicis) of Valeant
Pharmaceuticals (Valeant). Under the terms of the agreement, the partnership
will form physical loyalty program called the M^[^2^]VP Program
(Medicis-Mentor Valued Partner Program), which will offer the MENTOR line of
breast implant products for the aesthetics (non-reimbursed) market, and
Medicis non-reimbursed facial aesthetic products, including neurotoxin,
fillers, and skin care. Mentor said that the program rewards the use of
various products across the Mentor and Medicis portfolios, allowing
participants to earn points which establish status within the program and can
be redeemed for product purchases. David J. Wilson, Worldwide President of
Mentor said, "We believe the creation of a combined loyalty program allows
both organizations to deliver more value and choice to plastic surgeons
operating in an increasingly competitive market." The Full Research Report on
Johnson & Johnson - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/0ba3_JNJ]

--

Zoetis Inc. Research Report

On July 2, 2013, Zoetis Inc. (Zoetis) announced its plans to expand its
manufacturing facility in Lincoln, Nebraska, to ensure consistent supply of
high-quality, reliable medicines for veterinarians, livestock producers, and
animals under their care. The Company intends to add in a 19,000 square-foot,
three-story to the existing production facility by 2014, so as to accommodate
the transfer of products from a third-party manufacturer to Lincoln. With the
upcoming expansion, Zoetis aims to affirm its longstanding commitment to being
a world-class manufacturer of animal health products. Zoetis currently
employs more than 500 people at its Lincoln plant, and it expects the
expansion to create as many as 30 new positions at peak production time. The
Full Research Report on Zoetis Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/7e28_ZTS]

--

CVS Caremark Corporation Research Report

On July 1, 2013, CVS/pharmacy, the retail division of CVS Caremark Corporation
(CVS Caremark), announced the launch of its new Drug Interaction Checker as a
part of its top-rated CVS Mobile app. According to CVS/pharmacy, the app
allows customers to check for potential drug interactions by comparing
over-the-counter (OTC) products with their prescriptions and other OTCs on
their smartphones. The users need to enter the name of the product or active
ingredients and the new app compares the available product details against the
OTCs or prescription medications that are entered or imported through the
patient's secure pharmacy history. Later, it identifies the possible
interactions based on a comprehensive and continually updated database of drug
information to alert users of any potential issues. CVS Caremark said that the
Drug Interaction Checker adds to the already existing pack of health resources
offered on the CVS Mobile app, and is available as a free download from
Apple's App Store or through Google Play. Current users can update their
existing app to instantly receive the new feature. The Full Research Report on
CVS Caremark Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/f831_CVS]

--

Omnicare, Inc. Research Report

On July 5, 2013, Omnicare, Inc. (Omnicare) announced the appointment of James
(Jim) Carlson to its Board of Directors, effective July 1, 2013. Mr. Carlson
served as CEO of Amerigroup Corporation (Amerigroup) from 2007 to 2012, and
became the chairman of Amerigroup's Board of Directors in 2008. Omnicare
stated that under Mr. Carlson's leadership, Amerigroup more than doubled the
number of state Medicaid programs it served, as well as recorded more than
four-fold growth in its revenues. With Mr. Carlson's appointment, the
Company's Board has now expanded to ten directors, nine of whom are
independent. The Full Research Report on Omnicare, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/e195_OCR]

--

Novartis AG (ADR) Research Report

On July 5, 2013, Novartis AG (ADR) (Novartis) announced that the European
Commission has granted the Company a new indication for Lucentis (ranibizumab)
to treat patients with visual impairment due to choroidal neovascularization
(CNV) secondary to pathologic myopia (myopic CNV). According to Novartis, this
makes Lucentis the first anti-VEGF (vascular endothelial cell growth factor)
therapy licensed for four indications in the European Union. Novartis said
that RADIANCE, the Company sponsored clinical trials in patients with myopic
CNV, showed that Lucentis provides rapid and superior improvement in visual
acuity compared with the current standard of care, Visudyne (verteporfin). The
trial also revealed that in patients with myopic CNV, there is an average
14-letter visual acuity gain in the first year with a median of 2 injections,
and over 60% of patients in RADIANCE did not need further injections after six
months. The Full Research Report on Novartis AG (ADR) - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/956c_NVS]

--

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com, Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.